Law library  /  MPDG  /  Section 59
Medical Devices Implementation Act · Chapter 4 · Clinical investigations, performance studies and other clinical investigations
Section 59

Implementation of substantial modifications

§ 59 MPDG · Vornahme von wesentlichen Änderungen

Medizinprodukterecht-Durchführungsgesetz (MPDG) · German text as of 29 October 2026 · translation edited by Alexander Baranov

#

The sponsor may implement the substantial modification applied for no earlier than 38 days after receipt of the communication from the competent ethics committee confirming receipt of the application in proper form, unless the competent ethics committee has issued an unfavourable opinion within the time limit under section 51(1).

Der Sponsor darf die beantragte wesentliche Änderung frühestens 38 Tage nach Erhalt der Mitteilung der zuständigen Ethik-Kommission über den Eingang des ordnungsgemäßen Antrags vornehmen, es sei denn, die zuständige Ethik-Kommission hat innerhalb der Frist nach § 51 Absatz 1 eine ablehnende Stellungnahme abgegeben.

Does § 59 MPDG affect your product?

Background: Running a clinical trial in Germany · MDR vs IVDR in Germany · EU Authorised Representative and PRRC. We explain what this provision means for your launch, price and timeline — fixed price, in writing.

Unofficial translation for information only. Only the German text is legally binding. German text: consolidated version from gesetze-im-internet.de, retrieved 29 October 2026. Where German statutes use “soll”, “shall” denotes an obligation that admits exceptions in atypical cases. Not legal advice.